Biotech Values

[DewDiligence]

Re: COVID-vaccine pricing in the commercial market

Starting in 1Q23—or whenever supplies under existing contracts government run out—PFE will begin selling its COVID vaccine in the US commercial market with a list price of $110-130 per single-use vial, which is about 4x the price per dose PFE realized from doses sold to the US and EU under government contracts. There will be some rebating/discounting of the commercial list price but this is nevertheless a big commercial opportunity, even with greatly reduced volume compared to the early days of the pandemic.

The list price for ex-US commercial sales has yet to be determined.

Source: Today’s PFE CC.